Vireo Growth is trading against the grain of its sector this week — down 2.9% over five days to CAD 16.70 while virtually every correlated cannabis peer posted solid gains.
The peer divergence is striking. CURA gained 16.4% on the week. WEED added 7.0%, TSND rose 7.7%, and TLRY climbed 6.0%. Vireo moved the other way, even as the stock managed a 2.0% bounce on the final session of the week to close at CAD 16.70. The one-month picture is more flattering — up nearly 12% — but this week's relative weakness against a strongly bid sector is the standout tension.
The borrow market tells a story of rapid normalization after an earlier stress episode. At the start of September, cost to borrow ran as high as 34% and availability was genuinely squeezed — the 52-week tightest reading was 312% availability, reached on September 3. Since then the lending market has loosened sharply. Cost to borrow has fallen to 6.3%, down 41% on the week, and availability has opened back up to effectively uncapped levels, with roughly 716,000 shares free to borrow. Short interest itself is only 0.0007% of the float — a negligible position even after rising 534% on a week-over-week basis, which in absolute terms amounts to roughly 6,800 shares short. There is no meaningful short pressure here. The earlier CTB spike looks more like a thin-float, low-liquidity technical event than a sustained positioning story.
The ownership register is the more newsworthy angle. Vireo Growth carries multiple active Schedule 13D filers on its register, which is notable for a micro-cap cannabis name. CHICAGO ATLANTIC GP HOLDINGS holds a disclosed 36.7% stake, Keith Capurro filed a 13D at 6.47%, Christopher Jeffery holds 8.6%, and Co-Executive Chairman Kyle Kingsley carries a 6.0% 13D position. These are event-driven disclosures around the 5% threshold — stakes are as last disclosed, and holders who drift below 5% may not file again — but the concentration of 13D filers signals a register where strategic intent is explicitly on record. Two Tails Story Co. holds a further 14.5% on the institutional side, and Chicago Atlantic Advisers adds 7.4%, making the top two holders alone responsible for over half the reported share count.
The ORTEX short score has eased meaningfully this week, dropping to 30.6 from a recent high near 49 on September 9. That softening reflects the loosening borrow conditions and the nominal short interest level. The composite stock score sits at 72.6, driven by an exceptional growth pillar score of 96.1 — the company's f-score of 6 and positive return on assets are doing the heavy lifting there — while momentum remains weak with relative strength deeply negative across 91-day and 182-day windows. The next earnings event is scheduled for November 11, and the two most recent prints produced next-day moves of 3.7% and 6.4% — modest by cannabis standards, but worth framing given Vireo's thin float and concentrated ownership.
With borrow conditions now loose and short interest negligible, the watch points into November are whether the cannabis sector bid holds and carries Vireo along with it — or whether this week's relative underperformance against peers like CURA and WEED signals a company-specific drag that the November earnings print will need to address.
See the live data behind this article on ORTEX.
Open VREO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
